Pain Management News

WASHINGTON — Pain in patients scheduled for total knee arthroplasty demonstrates no relation to physical activity, suggesting pain relief alone may not improve activity after the procedure, according to a speaker at ACR Convergence 2024.

The FDA has cleared an investigational new drug application for an epigenetic regulator to treat intractable pain due to idiopathic small fiber neuropathy, according to the manufacturer.

WASHINGTON — Patients treated with a novel neurotrophin-3 inhibitor demonstrated significant reductions in osteoarthritis knee pain across all dosing levels, according to data presented at ACR Convergence 2024.

Despite a lack of “gold standard” evidence surrounding cannabis use for musculoskeletal pain, rheumatologists must not turn a blind eye to how such products are used by their patients in the real world, according to researchers.

A single saline injection, openly prescribed as a placebo, yielded approximately 1 month of chronic back pain improvement, along with longer-term benefits in depression and sleep, according to data published in JAMA Network Open.

Knee osteoarthritis pain responds best to exercise combined with a non-exercise intervention, such as diet, while hip osteoarthritis moderately benefits from non-exercise interventions vs. resistance exercise, according to data.

SAN DIEGO — Improving depressive symptoms can reduce patients’ chronic pain, according to a presenter at the 2024 Congress of Clinical Rheumatology West.

In the third episode of the NSAIDs saga, we focus on COX-2 inhibition! Did the hopes and dreams of selective COX-2 inhibition pan out? What can the rise and fall of VIOXX teach us about physiology?

Opioid use in patients with autoimmune rheumatic disease has decreased 15% annually since 2014, while use of non-opioid options for pain management has either increased or stabilized, according to data published in The Lancet Rheumatology.